[{"orgOrder":0,"company":"Chinese Academy of Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Boceprevir","moa":"HCV proteases\/NS3-4A serine protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Chinese Academy of Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Chinese Academy of Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Chinese Academy of Sciences \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Boceprevir

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Chinese Academy of Sciences

                          Country arrow
                          2024 ACI Convention
                          Not Confirmed

                          Chinese Academy of Sciences

                          Country arrow
                          2024 ACI Convention
                          Not Confirmed

                          Details : Boceprevir and GC376, can inhibit the enzymatic activity well from 18 chemical drugs by in vitro fluorescence resonance energy transfer (FRET) enzymatic assays.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 14, 2020

                          Lead Product(s) : Boceprevir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank